Linda Maxwell - 22 Jul 2026 Form 4 Insider Report for UNITED THERAPEUTICS Corp (UTHR)

Reporting relationship: Director
Issuer ticker: UTHR
Reported as of: 22 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 Jul 2026, 16:46:05 UTC
Prior SEC filing: 10 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ John S. Hess, Jr. under Power of Attorney

Key filing fact

Linda Maxwell filed Form 4 for UNITED THERAPEUTICS Corp (UTHR) on 23 Jul 2026.

Key facts

This page summarizes Linda Maxwell's Form 4 filing for UNITED THERAPEUTICS Corp (UTHR).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 23 Jul 2026, 16:46.

Change

Previous filing in this sequence was filed on 10 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001822674 Primary reporting owner

MAXWELL LINDA

Relationship: Director
Address: C/O UNITED THERAPEUTICS CORPORATION, 1000 SPRING STREET, SILVER SPRING
Signature: /s/ John S. Hess, Jr. under Power of Attorney
Signature date: 23 Jul 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

UTHR transaction Derivative

Restricted Stock Unit

Award

Transaction value
Shares: +380
Change %
Price: $0.000000^*
Shares after: 380
Date: 22 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 380
Exercise price: $0.000000
Footnotes: F1, F2, F3, F4

UTHR transaction Derivative

Stock Option

Award

Transaction value
Shares: +1,190
Change %
Price: $0.000000^*
Shares after: 1,190
Date: 22 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,190
Exercise price: $527.07
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

Footnote F2

Annual non-employee director award.

Footnote F3

Annual non-employee director awards become fully vested on the earlier to occur of (a) the one-year anniversary of the grant date; or (b) the date of the next Annual Meeting of Shareholders following the grant date. June 25, 2027 is the anticipated date of the next Annual Meeting of Shareholders.

Footnote F4

Not applicable as restricted stock units do not have an expiration date.